222 related articles for article (PubMed ID: 30223294)
1. Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors.
Stevelink R; Koeleman BPC; Sander JW; Jansen FE; Braun KPJ
Eur J Neurol; 2019 Jun; 26(6):856-864. PubMed ID: 30223294
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of factors related to first line drugs refractoriness in patients with juvenile myoclonic epilepsy (JME).
Fayad C; Saad K; Kahwagi GJ; Hallit S; Griffin D; Abou-Khalil R; El-Hayek E
PLoS One; 2024; 19(4):e0300930. PubMed ID: 38593118
[TBL] [Abstract][Full Text] [Related]
3. Relapse after treatment withdrawal of antiepileptic drugs for Juvenile Absence Epilepsy and Juvenile Myoclonic Epilepsy.
Healy L; Moran M; Singhal S; O'Donoghue MF; Alzoubidi R; Whitehouse WP
Seizure; 2018 Jul; 59():116-122. PubMed ID: 29807291
[TBL] [Abstract][Full Text] [Related]
4. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
[TBL] [Abstract][Full Text] [Related]
5. Clinical heterogeneity of juvenile myoclonic epilepsy: follow-up after an interval of more than 20 years.
Syvertsen MR; Thuve S; Stordrange BS; Brodtkorb E
Seizure; 2014 May; 23(5):344-8. PubMed ID: 24512779
[TBL] [Abstract][Full Text] [Related]
6. Seizure outcome in 175 patients with juvenile myoclonic epilepsy--a long-term observational study.
Höfler J; Unterberger I; Dobesberger J; Kuchukhidze G; Walser G; Trinka E
Epilepsy Res; 2014 Dec; 108(10):1817-24. PubMed ID: 25443450
[TBL] [Abstract][Full Text] [Related]
7. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis.
Stevelink R; Al-Toma D; Jansen FE; Lamberink HJ; Asadi-Pooya AA; Farazdaghi M; Cação G; Jayalakshmi S; Patil A; Özkara Ç; Aydın Ş; Gesche J; Beier CP; Stephen LJ; Brodie MJ; Unnithan G; Radhakrishnan A; Höfler J; Trinka E; Krause R; ; Irelli EC; Di Bonaventura C; Szaflarski JP; Hernández-Vanegas LE; Moya-Alfaro ML; Zhang Y; Zhou D; Pietrafusa N; Specchio N; Japaridze G; Beniczky S; Janmohamed M; Kwan P; Syvertsen M; Selmer KK; Vorderwülbecke BJ; Holtkamp M; Viswanathan LG; Sinha S; Baykan B; Altindag E; von Podewils F; Schulz J; Seneviratne U; Viloria-Alebesque A; Karakis I; D'Souza WJ; Sander JW; Koeleman BPC; Otte WM; Braun KPJ
EClinicalMedicine; 2022 Nov; 53():101732. PubMed ID: 36467455
[TBL] [Abstract][Full Text] [Related]
8. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up.
Geithner J; Schneider F; Wang Z; Berneiser J; Herzer R; Kessler C; Runge U
Epilepsia; 2012 Aug; 53(8):1379-86. PubMed ID: 22686598
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors.
Senf P; Schmitz B; Holtkamp M; Janz D
Neurology; 2013 Dec; 81(24):2128-33. PubMed ID: 24212391
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of higher drug load for seizure freedom in idiopathic generalized epilepsy: Comparison between juvenile myoclonic epilepsy and other types.
Kitazawa Y; Jin K; Kakisaka Y; Fujikawa M; Tanaka F; Nakasato N
Epilepsy Res; 2018 Aug; 144():20-24. PubMed ID: 29729533
[TBL] [Abstract][Full Text] [Related]
11. Phenotyping juvenile myoclonic epilepsy. Praxis induction as a biomarker of unfavorable prognosis.
Uchida CG; de Carvalho KC; Guaranha MS; Guilhoto LM; de Araújo Filho GM; Wolf P; Yacubian EM
Seizure; 2015 Nov; 32():62-8. PubMed ID: 26552565
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
13. Antiepileptic drug withdrawal in juvenile myoclonic epilepsy.
Syvertsen M; Fløgstad I; Enger U; Landmark CJ; Koht J
Acta Neurol Scand; 2019 Feb; 139(2):192-198. PubMed ID: 30378684
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific disease modifiers in juvenile myoclonic epilepsy.
Shakeshaft A; Panjwani N; Collingwood A; Crudgington H; Hall A; Andrade DM; Beier CP; Fong CY; Gardella E; Gesche J; Greenberg DA; Hamandi K; Koht J; Lim KS; Møller RS; Ng CC; Orsini A; Rees MI; Rubboli G; Selmer KK; Striano P; Syvertsen M; Thomas RH; Zarubova J; Richardson MP; Strug LJ; Pal DK
Sci Rep; 2022 Feb; 12(1):2785. PubMed ID: 35190554
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic analysis of juvenile myoclonic epilepsy in Indian families.
Jain S; Tripathi M; Srivastava AK; Narula A
Acta Neurol Scand; 2003 May; 107(5):356-62. PubMed ID: 12713528
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of juvenile myoclonic epilepsy in people <30 years of age-A population-based study in Norway.
Syvertsen M; Hellum MK; Hansen G; Edland A; Nakken KO; Selmer KK; Koht J
Epilepsia; 2017 Jan; 58(1):105-112. PubMed ID: 27861775
[TBL] [Abstract][Full Text] [Related]
17. Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Syvertsen M; Baftiu A; Enger U; Koht J; Johannessen SI
Epilepsy Behav; 2019 Sep; 98(Pt A):110-116. PubMed ID: 31330379
[TBL] [Abstract][Full Text] [Related]
18. Topiramate monotherapy for juvenile myoclonic epilepsy.
Liu J; Wang LN; Wang YP
Cochrane Database Syst Rev; 2015 Dec; (12):CD010008. PubMed ID: 26695884
[TBL] [Abstract][Full Text] [Related]
19. Myoclonic status epilepticus in juvenile myoclonic epilepsy.
Larch J; Unterberger I; Bauer G; Reichsoellner J; Kuchukhidze G; Trinka E
Epileptic Disord; 2009 Dec; 11(4):309-14. PubMed ID: 20045780
[TBL] [Abstract][Full Text] [Related]
20. Juvenile myoclonic epilepsy: Long-term prognosis and risk factors.
Pietrafusa N; La Neve A; de Palma L; Boero G; Luisi C; Vigevano F; Specchio N
Brain Dev; 2021 Jun; 43(6):688-697. PubMed ID: 33781581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
